Erratum: What is required to end the AIDS epidemic as a public health threat by 2030? The cost and impact of the fast-track approach (PLoS ONE (2016) 11:5 (e0154893) DOI: 10.1371/journal.pone.0154893);What is required to end the AIDS epidemic as a public health threat by 2030? The cost and impact of the fast-track approach

PLoS ONE

Volumn 11, Issue 5, 2016, Pages

  Stover, John ^a   Bollinger, Lori ^a   Antonio Izazola, Jose ^b   Loures, Luiz ^b   DeLay, Paul ^c   Ghys, Peter D ^b   Dybul, Mark ^d   Bidault, Nicolas ^d   Onyekwena, Obinna ^d   Blakely, Matt ^d   Hijazi, Mai ^e   Montaner, Julio ^f   Over, Mead ^g   Vassall, Anna ^h   Brown, Timothy ⁱ   Diamond, Samantha ^j   Tagar, Elya ^j   Eaton, Jeffrey ^k   Williams, Brian ^l   Webb, Douglas ^m   Idele, Priscilla A ⁿ   Lauer, Jeremy Addison ^o   Weiler, Gundo Aurel ^o   Benedikt, Clemens ^p   Cohen, Jennifer ^q   Izazola, Jose A ^b   Valladares, Ricardo ^b   Zekeng, Leopold ^b   Semini, Iris ^b   Burgos Filho, Ruy ^r   Masiye, Felix ^r   Meyer Rath, Gesine ^r   more..

^a AVENIR HEALTH   (United States)

^b UNAIDS   (Switzerland)

^c Economist and Gender Specialist   (United States)

^d Global Fund   (Switzerland)

^e Office of HIV/AIDS   (United States)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g CENTER FOR GLOBAL DEVELOPMENT   (United States)

^h LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

ⁱ East West Center   (United States)

^j CLINTON HEALTH ACCESS INITIATIVE   (United States)

^k IMPERIAL COLLEGE LONDON   (United Kingdom)

^l STELLENBOSCH UNIVERSITY   (South Africa)

^m Bureau Crisis Prevention/Recovery   (Switzerland)

ⁿ UNICEF   (United States)

^o WORLD HEALTH ORGANIZATION   (Switzerland)

^p WB   (United States)

^q MSF   (Switzerland)

^r UNAIDS ^*  (South Africa)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL THERAPY; ARTICLE; DEATH; DISEASE SURVEILLANCE; EPIDEMIC; FAST TRACK APPROACH; GEOGRAPHIC DISTRIBUTION; HEALTH CARE COST; HEALTH CARE PLANNING; HUMAN; INFECTION PREVENTION; LOWEST INCOME GROUP; PUBLIC HEALTH; TREND STUDY; ACQUIRED IMMUNODEFICIENCY SYNDROME; COST; ECONOMICS; HISTORY; PUBLIC HEALTH SERVICE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; COSTS AND COST ANALYSIS; HISTORY, 21ST CENTURY; HUMANS; PUBLIC HEALTH PRACTICE;

EID: 84969820610     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0158253     Document Type: Erratum

References (22)

1. Schwartländer B, Stover J, Hallett T, Atun R, Avila C, Gouws E, et al. (2011) Towards an improved investment approach for an effective response to HV/AIDS. Lancet 377(9782):2031-2041. PMID: 21641026
2. United Nations General Assembly. Political Declaration on HIV/AIDS: Intensifying our Efforts to Eliminate HIV/AIDS. New York, 2011.
3. Stover J, Hallett TB, Wu Z, Warren M, Gopalappa C, Pretorius, et al. How Can We Get Close to Zero? The Potential Contribution of Biomedical Prevention and the Investment Framework towards an Effective Response to HIV PLoS One 9(11):e111956. doi: 10.1371/journal.pone.0111956 PMID: 25372770
4. Avenir Health, Spectrum Manual: Spectrum System of Policy Models, available at http://avenirhealth.org/Download/Spectrum/Manuals/SpectrumManualE.pdf
5. Bollinger L. RNM: A Computer Program for Estimating the Costs of Implementing an HIV/AIDS Program, USAID | Health Policy Initiative, Futures Group, August 2013.
6. Baird SJ, Garfein RS, McIntosh CT, Ozler B. Effect of cash transfer programmes for schooling on prevalence of HIV and herpes simplex type 2 in Malawi: a cluster randomized trial. Lancet 2012; 379: 1320-20. PMID: 22341825
7. Karim QA, Impact of conditional cash incentives on HSV-2 and HIV in rural high school students in South Africa. CAPRISA 007 matched - pair cluster randomized controlled trial, presented at IAS 2015, Vancouver, July 2015.
8. Pettifor A, MacPhail C, Selin A, Gomez-Olive X, Hughes J, et al. HPTN 068 conditional cash transfer to prevent HIV infection among young women in South Africa: results of a randomized controlled trial, abstract TUACO106LB, IAS 2015, Vancouver, July 2015.
9. Rollins N, Mahy M, Becquet R, Kuhn L, Creek T, Mofenson L. Estimates of peripartum and postnatal mother-to-child transmission probabilities for use in Spectrum and other population-based models. Sex Transm Infect 2012; 88:i44-i51. doi: 10.1136/sextrans-2012-050709 PMID: 23172345
10. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, et al. (2005) Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: The ANRS 1265 Trial. PLoS Med 2: e298. doi: 10.1371/journal.pmed.0020298 PMID: 16231970
11. Bailey RC, Moses S, Parker CB, Agot K, Maclean I, et al. (2007) Male circumcision for HIV prevention in young men in Kisumu, Kenya: A randomised controlled trial. Lancet 369: 643-656. PMID: 17321310
12. Gray RH, Kigozi G, Serwadda D, Makumbi F, Watya S, et al. (2007) Male circumcision for HIV prevention in men in Rakai, Uganda: A randomised trial. Lancet 369: 657-666. PMID: 17321311
13. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, et al. on behalf of the CAPRISA 004 Trial Group (2010) Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women. Science 329(5996): 1168-1174.
14. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, et al. (2010) Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men. N Engl J Med 363(27): 2587-2599. doi: 10.1056/NEJMoa1011205 PMID: 21091279
15. Baeten JM, Donnell D, Ndase P, Mugo N, Campbell JD, et al. (2012) Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women. N Engl J Med 367(5): 399-410. doi: 10.1056/NEJMoa1108524 PMID: 22784037
16. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, et al. (2012); Antiretroviral Preexposure Prophylaxis for Heterosexual HIV Transmission in Botswana. N Engl J Med 367: 423-34. doi: 10.1056/NEJMoa1110711 PMID: 22784038
17. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipur MC, Kumarasamy N, et al. Prevention of HIV-1 Infection with Early Antiretroviral Therapy, N Engl J Med 2011; 365:493-505 doi: 10.1056/NEJMoa1105243 PMID: 21767103
18. Stover J, Andreev K, Slaymaker E, Gopalappa C, Sabin K, Velasquez C et al. Updates to the Spectrum model to estimate key HIV indicators for adults and children. AIDS 2014 28 (Suppl 4):S427-S434. doi: 10.1097/QAD.0000000000000483 PMID: 25406748
19. United Nations. World Population Prospects: Key findings & advance tables: 2015 Revision, ESA/P/WP.241. United Nations, New York, 2015
20. WHO. Guidelines on When to Start Antiretroviral Therapy and on Pre-Exposure Prophylaxis for HIV, September 2015.
21. Yiannoutsos CT, Johnson LF, Boulle A, Musick BS, Gsponer T, Balestre E, et al. Estimated mortality of adult HIV-infected patients starting treatment with combination antiretroviral therapy. Sex Transm Infect 2012; 88:i33-i43. doi: 10.1136/sextrans-2012-050658 PMID: 23172344
22. United Nations General Assembly. Transforming our world: the 2030 Agenda for Sustainable Development. Resolution adopted by the General Assembly on 25 September 2015, Seventieth Session. A/RES/70/1. 21 October 2015. Available: http://www.un.org/ga/search/view-doc.asp?symbol=A/RES/70/1&Lang=E